This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Dezapelisib
DrugBank Accession Number
DB16137
Background

Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 421.45
Monoisotopic: 421.1121075
Chemical Formula
C20H16FN7OS
Synonyms
  • Dezapelisib
External IDs
  • INCB-040093
  • INCB040093

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2K59L7G59M
CAS number
1262440-25-4
InChI Key
RSIWALKZYXPAGW-NSHDSACASA-N
InChI
InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1
IUPAC Name
6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one
SMILES
C[C@H](NC1=C2N=CNC2=NC=N1)C1=C(C(=O)N2C(C)=CSC2=N1)C1=CC=CC(F)=C1

References

General References
Not Available
ChemSpider
28651137
ChEMBL
CHEMBL2216863
ZINC
ZINC000095564453

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentRecurrent Adult Hodgkin's Lymphoma / Refractory Hodgkin Lymphoma1
1Active Not RecruitingTreatmentB-cell Malignancy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.031 mg/mLALOGPS
logP2.64ALOGPS
logP2.76ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)9.75ChemAxon
pKa (Strongest Basic)3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity115.92 m3·mol-1ChemAxon
Polarizability41.33 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 15, 2020 18:13 / Updated at February 21, 2021 18:55